A simulation study using validated prognostic factors to assess expected long-term survival

Methods of Information in Medicine

Volumn 44, Issue 4, 2005, Pages 577-583

  Pfirrmann, Markus ^a,b,c   Hasford, J ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b Gesell fur Statistik und Consulting   (Germany)

^c Immunotherapy Research Center GIS eV   (Germany)

Author keywords

Chronic; Cumulative survival rate; Imatinib mesylate; Myeloid leukemia; Prognosis

Indexed keywords

ALPHA INTERFERON; IMATINIB;

ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; HUMAN; KAPLAN MEIER METHOD; LEUKEMIA REMISSION; META ANALYSIS; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SURVIVAL TIME; SYSTEMATIC REVIEW;

EID: 25144451196     PISSN: 00261270     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1634010     Document Type: Conference Paper

References (22)

1. Sawyers CL. Chronic myeloid leukaemia. N Engl J Med 1999; 340: 1330-40.
2. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1497-501.
3. Stone RM. Optimizing Treatment of Chronic Myeloid Leukemia: A Rational Approach. Oncologist 2004; 9: 259-70.
4. Kantarjian H, Sawers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, for the international STI571 CML study group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-52.
5. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med 1996; 2: 561-6.
6. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ, for the IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
7. Hasford J, Pfirrmann M, Hochhaus A. How long will chronic phase CML patients treated with imatinib live? Blood 2003; 102: 905a.
8. Pfirrmann, Hasford J. On the expected survival advantage of imatinib over IFN in chronic phase CML patients. The Hematology Journal 2004; 5, Suppl. 2: S39.
9. Hasford J, Pfirrmann M, Hochhaus A. How long will chronic myeloid leukemia patients treated with imatinib mesylate live? Leukemia 2005; 19: 497-99.
10. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, Alimena G, Steegmann JL, Ansari H. A New Prognostic Score for Survival of Patients with Chronic Myeloid Leukemia Treated with Interferon Alfa. J Nat Cancer Inst 1998; 90: 850-8.
11. Bonifazi F, De Vivo A, Rosti G, Tiribelli M, Russo D, Trabacchi E, Fiacchini M, Montefusco E, Baccarani M.. Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with a-interferon. Br J Haematol 2000; 111: 587-95.
12. Pfirrmann M, Hasford J. Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with a-interferon: Comments. Br J Haematol 2001; 114: 241-2.
13. Pfirrmann M, Hasford J for the Collaborative CML Prognostic Factors Project (C.P.F.P.). Impact of time-dependent response variables on the prognosis of chronic myeloid leukaemia. Haematologica 2000; 85,
14. the Jubilee Meeting on CML, Suppl.: 22.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
16. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J of Clin Oncol 1983; 1: 710-9.
17. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-48.
18. Greenwood M. A report on the natural duration of cancer. Reports on Public Health and Medical Subjects, H.M. Stationary Office, London, 1926; 33: 1-26.
19. SAS Institute Inc., Cary, NC, USA, 1999.
20. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP, for the International Randomized Study of Interferon versus STI571 (IRIS) Study Group: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed patients with chronic myeloid leukemia. N Engl J Med 2003; 349: 1423-32.
21. Müller MC, Gattermann N, Lahaye T, Deininger MWN, Berndt A, Fruehauf S, Neubauer A, Fischer T, Hossfeld DK, Schneller F, Krause SW, Nerl C, Sayer HG, Ottmann OG, Waller C, Aulitzky W, le Coutre P, Freund M, Merx K, Paschka P, König H, Kreil S, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A. Dynamics of BCR-ABL mRNA expression in first line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C. Leukemia 2003; 17: 2392-400.
22. Kantarjian HM, Cortes JE, O'Brien S, Luthra R, Giles F, Verstovsek S, Faderl S, Thomas D, Garcia-Manero G, Rios MB, Shan J, Jones D, Talpaz M. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive, chronic-phase chronic myeloid leukemia after failure of interferon α. Blood 2004; 104: 1979-88.